Skip to main content
Premium Trial:

Request an Annual Quote

Celera Adds GeneFormatics Protein Database to Discovery System

SAN FRANCISCO, Oct. 29 – Celera Genomics will include GeneFormatics’ structural proteomics database in its Discovery System, the companies announced Monday.

San Diego, Calif.-based GeneFormatics’ Proteomics Database contains approximately 7,000 novel biochemical function and structure assignments for potential drug targets in humans, according to the company.

Financial details of the agreement were not disclosed.

“Knowledge of the biochemical function and structures of encoded proteins are critical to leveraging the value of genomic data in structure-based drug design processes,” John Chiplin, CEO of GeneFormatics, said in a statement.

Earlier in the month, GeneFormatics raised $22 million in its third round of financing.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.